Revenues Working Against Editas Medicine, Inc.'s (NASDAQ:EDIT) Share Price Following 34% Dive
Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
Insider Sellers Might Regret Selling Editas Medicine Shares at a Lower Price Than Current Market Value
Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event
CRISPR, Beam, Other Gene Editing Names up Significantly
Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $4